Humanized antibodies against CD269 (BCMA)

US10144782B2 · kind B2 · utility

Assignee

• Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft · DE

Inventors

• Felix Oden · Berlin, DE
• Stephen Marino · Berlin, DE
• Oliver Daumke · Berlin, DE

Key dates

• Filing date: Apr 30, 2015
• Grant date: Dec 4, 2018
• Expiry date: Apr 30, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N15/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to humanized antibodies or antibody fragments that bind CD269 (BCMA), thereby disrupting the interaction between CD269 and its native ligands (BAFF and APRIL), and their use in the treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.